Hopstem Secures Latest Funding Round

Hopstem secured an undisclosed amount in its latest Series C, adding another data point to the FinTech funding market.

Hopstem Raises an undisclosed amount in Funding

Hopstem Announces the first Closing of Series C Financing to Accelerate the Development of iPSC-Derived Forebrain Neural Cell Therapy.

Investors Behind the Funding

The round was backed by stroke. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Hopstem operates in FinTech. Hopstem's financing adds to recent private-market activity.

Strategic Use of Funds

Accelerate the Development of iPSC-Derived Forebrain Neural Cell Therapy.

Looking Ahead

Hopstem Announces the first Closing of Series C Financing to Accelerate the Development of iPSC-Derived Forebrain Neural Cell Therapy

Source reference: original announcement/article.